Unknown

Dataset Information

0

MET in glioma: signaling pathways and targeted therapies.


ABSTRACT: Gliomas represent the most common type of malignant brain tumor, among which, glioblastoma remains a clinical challenge with limited treatment options and dismal prognosis. It has been shown that the dysregulated receptor tyrosine kinase (RTK, including EGFR, MET, PDGFR?, ect.) signaling pathways have pivotal roles in the progression of gliomas, especially glioblastoma. Increasing evidence suggests that expression levels of the RTK MET and its specific stimulatory factors are significantly increased in glioblastomas compared to those in normal brain tissues, whereas some negative regulators are found to be downregulated. Mutations in MET, as well as the dysregulation of other regulators of cross-talk with MET signaling pathways, have also been identified. MET and its ligand hepatocyte growth factor (HGF) play a critical role in the proliferation, survival, migration, invasion, angiogenesis, stem cell characteristics, and therapeutic resistance and recurrence of glioblastomas. Therefore, combined targeted therapy for this pathway and associated molecules could be a novel and attractive strategy for the treatment of human glioblastoma. In this review, we highlight progress made in the understanding of MET signaling in glioma and advances in therapies targeting HGF/MET molecules for glioma patients in recent years, in addition to studies on the expression and mutation status of MET.

SUBMITTER: Cheng F 

PROVIDER: S-EPMC6585013 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

MET in glioma: signaling pathways and targeted therapies.

Cheng Fangling F   Guo Dongsheng D  

Journal of experimental & clinical cancer research : CR 20190620 1


Gliomas represent the most common type of malignant brain tumor, among which, glioblastoma remains a clinical challenge with limited treatment options and dismal prognosis. It has been shown that the dysregulated receptor tyrosine kinase (RTK, including EGFR, MET, PDGFRα, ect.) signaling pathways have pivotal roles in the progression of gliomas, especially glioblastoma. Increasing evidence suggests that expression levels of the RTK MET and its specific stimulatory factors are significantly incre  ...[more]

Similar Datasets

| S-EPMC9697723 | biostudies-literature
| S-EPMC10679229 | biostudies-literature
| S-EPMC9003388 | biostudies-literature
| S-EPMC6992617 | biostudies-literature
| S-EPMC6534064 | biostudies-literature
| S-EPMC8942886 | biostudies-literature
| S-EPMC2669548 | biostudies-literature
| S-EPMC9535022 | biostudies-literature
| S-EPMC3759196 | biostudies-literature
| S-EPMC5253284 | biostudies-literature